NLRP3 Inflammasome-Driven Pyroptosis and Brain-Derived Neurotrophic Factor in Cancer Drug Resistance: A Cell-Type-Resolved Framework

Background/Objectives: Resistance to cancer therapy is attributed to the tumour microenvironment, not to tumour-cell genotype alone. Pyroptosis, the gasdermin-executed lytic death programme triggered mainly by NLRP3, is oncosuppressive in one compartment and resistance-promoting in another. We resolve that divergence by compartment and place brain-derived neurotrophic factor (BDNF) upstream. Methods: Narrative, mechanism-oriented review. Four queries covering the sensor, pyroptotic execution, malignancy and BDNF were screened on title and abstract; retained sources measured at least one step of the cascade, and claims were graded. Results: Acute activation in neoplastic cells releases damage-associated molecular patterns and supports immunogenic cell death, whereas chronic sublytic activation in M2-polarised tumour-associated macrophages sustains interleukin-1β/18 signalling, regulatory T-cell and myeloid-derived suppressor cell expansion, angiogenesis and checkpoint-blockade failure. BDNF restrains inflammasome activation in non-neoplastic systems through nuclear factor-κB priming, mitophagy, KLF2-dependent restraint of hexokinase 1, membrane repair and necroptosis crosstalk; no study has measured BDNF, NLRP3 and pyroptotic execution together in a tumour. Conclusions: We propose that BDNF may set this threshold in tumours, and a four-type classification by BDNF and NLRP3 status to organise experiment, not treatment. It makes compartment, duration and repair capacity, not the pathway's presence, decide whether pyroptotic signalling favours or defeats therapy, and specifies what would falsify it.

Authors

Institutions

Publication Details

Journal
Medicina
Published
2026-11-17
DOI
https://doi.org/10.3390/medicina62112257
Primary Topic
Inflammasome and immune disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

NLRP3 Inflammasome-Driven Pyroptosis and Brain-Derived Neurotrophic Factor in Cancer Drug Resistance: A Cell-Type-Resolved Framework

Serenella Medici, Andrea Angius, Alessio Aligi Cogoni, Ciriaco Carru et al.
1 links
Medicina
Inflammasome and immune disorders
article

NLRP3 Inflammasome-Driven Pyroptosis and Brain-Derived Neurotrophic Factor in Cancer Drug Resistance: A Cell-Type-Resolved Framework

Serenella Medici, Andrea Angius, Alessio Aligi Cogoni, Ciriaco Carru, Donatella Coradduzza, Maria Rosaria De Miglio
article en

Abstract

Background/Objectives: Resistance to cancer therapy is attributed to the tumour microenvironment, not to tumour-cell genotype alone. Pyroptosis, the gasdermin-executed lytic death programme triggered mainly by NLRP3, is oncosuppressive in one compartment and resistance-promoting in another. We resolve that divergence by compartment and place brain-derived neurotrophic factor (BDNF) upstream. Methods: Narrative, mechanism-oriented review. Four queries covering the sensor, pyroptotic execution, malignancy and BDNF were screened on title and abstract; retained sources measured at least one step of the cascade, and claims were graded. Results: Acute activation in neoplastic cells releases damage-associated molecular patterns and supports immunogenic cell death, whereas chronic sublytic activation in M2-polarised tumour-associated macrophages sustains interleukin-1β/18 signalling, regulatory T-cell and myeloid-derived suppressor cell expansion, angiogenesis and checkpoint-blockade failure. BDNF restrains inflammasome activation in non-neoplastic systems through nuclear factor-κB priming, mitophagy, KLF2-dependent restraint of hexokinase 1, membrane repair and necroptosis crosstalk; no study has measured BDNF, NLRP3 and pyroptotic execution together in a tumour. Conclusions: We propose that BDNF may set this threshold in tumours, and a four-type classification by BDNF and NLRP3 status to organise experiment, not treatment. It makes compartment, duration and repair capacity, not the pathway's presence, decide whether pyroptotic signalling favours or defeats therapy, and specifies what would falsify it.

MedicinaVol. 62(11)
University of Sassari (IT), Azienda Ospedaliero Universitaria di Sassari (IT), Institute of Genetic and Biomedical Research (IT), National Research Council (IT)
Good health and well-being
Inflammasome and immune disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon